BIOMESNIL MEDICAL : revenue, balance sheet and financial ratios

BIOMESNIL MEDICAL is a French company founded 37 years ago, specialized in the sector Réparation de matériels électroniques et optiques. Based in MONTIVILLIERS (76290), this company of category PME shows in 2023 a revenue of 4.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - BIOMESNIL MEDICAL (SIREN 349290627)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue N/C 3 957 022 € 3 521 135 € 3 982 334 € 4 031 804 € 3 931 944 € N/C 2 515 418 € 2 528 618 €
Net income 123 136 € 86 206 € 16 857 € 316 373 € 110 725 € 93 395 € 11 214 € -8 092 € -40 899 €
EBITDA N/C 233 384 € 56 925 € 219 863 € 176 241 € 137 474 € N/C 11 483 € 2 942 €
Net margin N/C 2.2% 0.5% 7.9% 2.7% 2.4% N/C -0.3% -1.6%

Revenue and income statement

In 2024, BIOMESNIL MEDICAL generates positive net income of 123 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

123 136 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 66%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 31%. The balance between equity and debt is satisfactory.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

66.243%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

30.945%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

30.9%

Solvency indicators evolution
BIOMESNIL MEDICAL

Sector positioning

Debt ratio
66.24 2024
2022
2023
2024
Q1: 0.05
Med: 9.93
Q3: 29.51
Watch

In 2024, the debt ratio of BIOMESNIL MEDICAL (66.24) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
30.95% 2024
2022
2023
2024
Q1: 26.48%
Med: 50.0%
Q3: 62.83%
Average

In 2024, the financial autonomy of BIOMESNIL MEDICAL (30.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
2.1 years 2023
2022
2023
Q1: 0.0 years
Med: 0.07 years
Q3: 1.04 years
Watch

In 2023, the repayment capacity of BIOMESNIL MEDICAL (2.10) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 170.88. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

170.885

Liquidity indicators evolution
BIOMESNIL MEDICAL

Sector positioning

Liquidity ratio
170.88 2024
2022
2023
2024
Q1: 189.26
Med: 248.71
Q3: 335.97
Watch

In 2024, the liquidity ratio of BIOMESNIL MEDICAL (170.88) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
6.48x 2023
2022
2023
Q1: 0.0x
Med: 0.43x
Q3: 2.63x
Excellent

In 2023, the interest coverage of BIOMESNIL MEDICAL (6.5x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
BIOMESNIL MEDICAL

Positioning of BIOMESNIL MEDICAL in its sector

Comparison with sector Réparation de matériels électroniques et optiques

Valuation estimate

Based on 197 transactions of similar company sales (all years), the value of BIOMESNIL MEDICAL is estimated at 248 686 € (range 104 740€ - 651 810€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
197 transactions
104k€ 248k€ 651k€
248 686 € Range: 104 740€ - 651 810€
NAF 4 all-time Aggregated at NAF sub-class level

Valuation method used

Net Income Multiple
123 136 € × 2.0x = 248 687 €
Range: 104 740€ - 651 810€

Only this financial indicator is available for this company.

How is this estimate calculated?

This estimate is based on the analysis of 197 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Réparation de matériels électroniques et optiques)

Compare BIOMESNIL MEDICAL with other companies in the same sector:

Voir toutes les statistiques du secteur Réparation de matériels électroniques et optiques

Frequently asked questions about BIOMESNIL MEDICAL

What is the revenue of BIOMESNIL MEDICAL ?

The revenue of BIOMESNIL MEDICAL in 2023 is 4.0 M€.

Is BIOMESNIL MEDICAL profitable?

Yes, BIOMESNIL MEDICAL generated a net profit of 123 k€ in 2024.

Where is the headquarters of BIOMESNIL MEDICAL ?

The headquarters of BIOMESNIL MEDICAL is located in MONTIVILLIERS (76290), in the department Seine-Maritime.

Where to find the tax return of BIOMESNIL MEDICAL ?

The tax return of BIOMESNIL MEDICAL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does BIOMESNIL MEDICAL operate?

BIOMESNIL MEDICAL operates in the sector Réparation de matériels électroniques et optiques (NAF code 33.13Z). See the 'Sector positioning' section above to compare the company with its competitors.